Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eo...
Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eosinophilic chronic rhinosinusitis after endoscopic sinus surgery
About this item
Full title
Author / Creator
Publisher
Chichester, UK: John Wiley & Sons, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Chichester, UK: John Wiley & Sons, Ltd
Subjects
More information
Scope and Contents
Contents
Dupilumab, a human monoclonal antibody against interleukin‐4 (IL‐4) and IL‐13, has been approved for treating severe asthma and eosinophilic chronic rhinosinusitis (ECRS). Patients with ECRS are often candidates for endoscopic sinus surgery (ESS). However, a considerable number of patients have recurrent ECRS. ECRS is an important factor influencin...
Alternative Titles
Full title
Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eosinophilic chronic rhinosinusitis after endoscopic sinus surgery
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_92da879da07649e19949ccdaeeb58f67
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_92da879da07649e19949ccdaeeb58f67
Other Identifiers
ISSN
2051-3380
E-ISSN
2051-3380
DOI
10.1002/rcr2.804
